SAT0328 An open-label study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis

A Schorpion; M Shenin; R Neubauer; CT Derk

doi:10.1136/annrheumdis-2017-eular.3932

Article info

Poster Presentations

Scleroderma, myositis and related syndromes

SAT0328 An open-label study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis

Free

Authors

A Schorpion 1Division of Rheumatology, Hospital of the University of Pennsylvania PubMed articles Google scholar articles
M Shenin 2Division of Rheumatology, Thomas Jefferson University Hospital, Philadelphia, United States PubMed articles Google scholar articles
R Neubauer 1Division of Rheumatology, Hospital of the University of Pennsylvania PubMed articles Google scholar articles
CT Derk 1Division of Rheumatology, Hospital of the University of Pennsylvania PubMed articles Google scholar articles

Citation

Schorpion A, Shenin M, Neubauer R, et al

SAT0328 An open-label study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis

Annals of the Rheumatic Diseases 2017;76:896.

Publication history

First published June 15, 2017.

Online issue publication

January 09, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password